Tirzepatide — Research Guide
Tirzepatide is a dual GIP / GLP-1 receptor agonist peptide. It is widely used in incretin-class metabolic-signaling research as the reference dual-agonist control alongside single-target agonists (Semaglutide) and triple-target agonists (Retatrutide).
Research Use Only — Not FDA-Approved
Orion compounds are for in-vitro laboratory research only and are not for human consumption.
Product
Tirzepatide 10mg
Purity
98.8%
CAS
2023788-19-2
Single
$44.99
10-pack/vial
$33.74
Chemistry & identity
Tirzepatide (CAS 2023788-19-2, MW 4813.48 g/mol) is a 39-residue synthetic peptide with a C20 fatty-diacid moiety conferring extended in-solution persistence and albumin binding in published systems. Solid-phase synthesis; per-batch HPLC + MS verification on every Orion lot.
Research applications
- Dual GIP/GLP-1 receptor co-activation kinetics
- Comparative GLP-1R selectivity (vs Semaglutide)
- Receptor-bias signaling and β-arrestin recruitment profiles
- Long-acting peptide design and fatty-acid conjugation studies
- Incretin axis cell-line and ex-vivo pancreatic islet assays
Stability & storage
Lyophilized Tirzepatide stored at −20°C is stable for the labeled expiry. After reconstitution, refrigerate at 2–8°C and use within the in-solution stability window published in source literature.
Published half-life range
120h midpoint (lit. 108h – 132h)
Source: Coskun et al., Mol Metab 2018; clinical trial PK data. See the half-life calculator for predicted in-solution decay over time.
Direct comparisons
Related research guides
Retatrutide — Research Guide
Retatrutide is an investigational triple-agonist peptide that binds the GLP-1, GIP, and glucagon receptors. It is one of the most cited compounds in current incretin-class metabolic-signaling research and is studied alongside earlier dual and single agonists (Tirzepatide, Semaglutide) to isolate the contribution of glucagon co-agonism.
Semaglutide — Research Guide
Semaglutide is a single-target GLP-1 receptor agonist peptide and the canonical reference compound for GLP-1-receptor research. As the longest-running modern GLP-1 analogue with extensive literature, it serves as the baseline against which newer dual- and triple-agonists are compared.
FAQ
Why study Tirzepatide vs Semaglutide?
Both target GLP-1R. Tirzepatide adds GIP-receptor agonism. Direct comparison isolates the contribution of GIP co-agonism in incretin-class research models.
What's the half-life?
Published literature ranges support a long in-solution stability profile (≈ 5 days in human plasma per peer-reviewed PK studies). See the half-life calculator for the decay model.
Where does Orion source from?
Tirzepatide is sourced from a verified overseas synthesis partner and re-tested on receipt by an independent third-party analytical lab. Sourcing details are part of every batch's documentation.
Is this for human use?
No. In-vitro research use only. Not FDA-approved, not for human consumption.